AU2001250722A1 - Medicament for the treatment of diseases caused by parasitic protozoa - Google Patents

Medicament for the treatment of diseases caused by parasitic protozoa

Info

Publication number
AU2001250722A1
AU2001250722A1 AU2001250722A AU5072201A AU2001250722A1 AU 2001250722 A1 AU2001250722 A1 AU 2001250722A1 AU 2001250722 A AU2001250722 A AU 2001250722A AU 5072201 A AU5072201 A AU 5072201A AU 2001250722 A1 AU2001250722 A1 AU 2001250722A1
Authority
AU
Australia
Prior art keywords
treatment
parasitic protozoa
medicament
disease
trypanosomiasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250722A
Inventor
Anders Hofer
Lars Thelander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001250722A1 publication Critical patent/AU2001250722A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic protozoa. More specifically, said substance capable of suppressing toxic effects may be a nucleobase, such as a purine base or a nucleoside, while the glutamine analogue advantageously is 6-diazo-5-oxo-L-norleucine (DON). The invention also relates to a pharmaceutical composition as such for the treatment and/or prevention of a disease caused by a parasitic protozoa, wherein the disease is selected from the group consisting of malaria, leishmaniasis and trypanosomiasis, e.g. American trypanosomiasis (Chaga's disease), or African trypanosomiasis (African sleeping sickness).
AU2001250722A 2000-04-27 2001-04-20 Medicament for the treatment of diseases caused by parasitic protozoa Abandoned AU2001250722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001531 2000-04-27
SE0001531A SE0001531D0 (en) 2000-04-27 2000-04-27 Medication for the treatment of diseases caused by parasitic protozoa
PCT/SE2001/000864 WO2001080809A2 (en) 2000-04-27 2001-04-20 Medicament for the treatment of diseases caused by parasitic protozoa

Publications (1)

Publication Number Publication Date
AU2001250722A1 true AU2001250722A1 (en) 2001-11-07

Family

ID=20279443

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250722A Abandoned AU2001250722A1 (en) 2000-04-27 2001-04-20 Medicament for the treatment of diseases caused by parasitic protozoa

Country Status (8)

Country Link
US (1) US7157449B2 (en)
EP (1) EP1284725B1 (en)
AT (1) ATE384521T1 (en)
AU (1) AU2001250722A1 (en)
DE (1) DE60132581T2 (en)
ES (1) ES2298229T3 (en)
SE (1) SE0001531D0 (en)
WO (1) WO2001080809A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001395A2 (en) * 2004-10-04 2007-01-04 University Of South Carolina Prevention and treatment of influenza with glutamine antagonist agents
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
WO2016201307A1 (en) * 2015-06-12 2016-12-15 The United State of America, as represented by the Secretary, Dept. of Health and Human Services Glutamine antagonists for use in treating cerebral edema and cerebral malaria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445239A4 (en) * 1989-06-21 1992-03-25 The Catholic University Of America Anti-malarial composition and method of use
US5180714A (en) * 1990-10-31 1993-01-19 Health Research, Inc. Adenosine compounds for the treatment of diseases caused by parasitic protozoa
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
AU5825598A (en) 1997-01-21 1998-08-07 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced suppression of hiv-1 by the combination of cytidine nucleoside analogues and ctp synthase inhibitors

Also Published As

Publication number Publication date
ES2298229T3 (en) 2008-05-16
WO2001080809A2 (en) 2001-11-01
DE60132581T2 (en) 2009-01-29
EP1284725B1 (en) 2008-01-23
WO2001080809A3 (en) 2002-02-28
US20030109505A1 (en) 2003-06-12
SE0001531D0 (en) 2000-04-27
DE60132581D1 (en) 2008-03-13
EP1284725A2 (en) 2003-02-26
ATE384521T1 (en) 2008-02-15
US7157449B2 (en) 2007-01-02

Similar Documents

Publication Publication Date Title
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DK0853083T3 (en) Pyridylfuran and pyridylthiophene compounds and their pharmaceutical use
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20076219L (en) Pharmaceutical formulation with apomorphine for buccal administration
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
PL366726A1 (en) 4&#39;-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
BRPI0515896A (en) a compound or a pharmaceutically acceptable salt or ester thereof, a method for treating or prophylaxis a host infected with a flavivirus, pestivirus or hepacivirus infection, and a pharmaceutical composition for treating a host infected with a flavivirus, pestivirus or hepacivirus
BRPI0509074A (en) pharmaceutical compositions comprising thyroid receptor agonists
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
MXPA05008368A (en) Hiv inhibiting 1,2,4-triazines.
MX9706647A (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors.
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001250722A1 (en) Medicament for the treatment of diseases caused by parasitic protozoa
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
HUP0402062A2 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them
IL146142A0 (en) 2-substituted-5&#39;-o-(1-boranotriphosphate adenosine derivatives and pharmaceutical compositions comprising them for treatment of type 2 diabetes
HUP0401940A2 (en) Pharmaceutical compositions for diabetic neuropathy
HK1068344A1 (en) Dimeric compounds and their use as anti-viral agents
AU2003263455A1 (en) Pyrazole amides for treating hiv infections
AU2003264940A1 (en) Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases